BioVector® 支原体表达载体

BioVector® Mycoplasma Expression Vector

第一部分：中文说明

一、 产品基本信息与遗传学背景

• 载体类型：原核表达载体（支原体属特异性稳定表达质粒系统）

• 物种适用性：主要适用于肺炎支原体 (Mycoplasma pneumoniae)、生殖支原体 (Mycoplasma genitalium)、山羊支原体 (Mycoplasma capricolum) 及丝状支原体等。

• 遗传密码特异性（密码子优化核心）：

  • 关键遗传学屏障：支原体属（Mycoplasma）具有独特的遗传密码，将 UGA 终止密码子重新定义为编码色氨酸（Tryptophan, Trp）。

  • 设计要求：若在常规大肠杆菌表达载体中表达外源基因，遇到 UGA 会提前终止。本系统采用针对支原体特异性优化的密码子体系。若目标蛋白需在支原体内高效表达，其序列中的色氨酸位点必须对应 UGA；若在常规宿主中克隆，则需注意此密码子偏好性的切换。

• 复制子与维持元件：

  • 携带源自支原体天然质粒（如 pGyl 类似物）的支原体特异性复制起始位点（oriC），确保其在支原体细胞分裂时能稳定分配。

  • 包含大肠杆菌复制子（如 pUC ori），用于在 E. coli 菌株中进行高拷贝克隆与质粒扩增。

• 筛选标记：通常配置四环素抗性基因（tetM）或红霉素抗性基因（ermB），该类标记由支原体强启动子驱动，用于在转化后的支原体中进行稳定抗性筛选。

二、 分子结构特征与克隆环境

• 启动子系统：由支原体高表达延伸因子启动子（如 P_tuf）或核糖体蛋白亚基启动子（如 P_rpsD）驱动，确保外源基因在缺乏复杂转录调控机制的支原体胞内实现持续高水平的组成型表达。

• 多克隆位点（MCS）：配置常用的独特性限制性内切酶切点（如 BamHI, EcoRI, XhoI, HindIII 等），方便外源片段的精准插入。

• 标签选择（Tags）：通常可选融合 C-端或 N-端的 6×His-tag、Flag-tag，便于后续利用免疫印迹（Western Blot）或亲和层析对支原体表达产物进行鉴定与纯化。

• 生物安全级别：1级或2级（BSL-1 / BSL-2）。载体本身为安全的原核质粒，但当其转化入致病性支原体（如肺炎支原体）时，后续的细胞培养与操作必须严格在二级生物安全柜中进行。

三、 转化与筛选标准操作步骤

1. 大肠杆菌扩增与质粒制备：

   • 将载体质粒转化至常规大肠杆菌受体菌（如 DH5α、Top10），接种于含相应抗生素（如氨苄青霉素或红霉素）的 LB 培养基中。

   • 37°C 振荡培养过夜，使用无毒素或高纯度质粒提取试剂盒提取质粒，测序验证 MCS 区段插入方向及读码框的正确性。

2. 支原体电转化（Electroporation）：

   • 收集处于对数生长期的支原体液体培养物，利用冰冷的高渗清洗液（如 8-272 mM 的蔗糖溶液或电转缓冲液）进行多次洗涤，制备高密度的支原体电转感受态细胞。

   • 取 50–100 μL 感受态细胞悬液置于预冷的电转杯中，加入 1–5 μg 的高纯度纯化质粒，混匀后冰孵。

   • 根据具体的支原体种属设置电击参数（通常为高电压、短时间冲入，如：电压 1.25–2.5 kV，电容 25 μF，电阻 100–400 Ω）。

   • 电击后立即加入预热的支原体完全肉汤培养基（如 SP4 或 Hayflick 培养基），在无抗生素条件下于 37°C 复苏培养 2–4 小时，以恢复膜完整性并表达抗性标记。

3. 抗性平板筛选：

   • 将复苏后的菌液涂布于含有对应筛选抗生素（如 2–10 μg/mL 四环素或红霉素）的支原体固体琼脂平板上。

   • 置于 37°C 恒温（或 5% $CO_2$ 微需氧环境）下培养 5–14 天，直至平板上长出特征性的“油煎蛋”状支原体转化子菌落。

四、 核心科研应用方向

1. 支原体基因功能验证与补救实验（Complementation）：用于将野生型基因导入基因敲除或突变的支原体弱毒株中，恢复其表型，从而确证特定基因（如粘附素、毒力因子）的功能。

2. 支原体表面抗原与疫苗靶点表达：在支原体本土系统中表达并展示高度构象依赖性的表面膜蛋白，用于研究宿主-病原体相互作用，或开发针对支原体感染的新型亚单位疫苗。

3. 病原体宿主互作分子机制研究：通过融合表达荧光蛋白（如 GFP、mCherry），在细胞水平实时动态示踪支原体对宿主上皮细胞的粘附、入侵及胞内定殖过程。

PART 2: ENGLISH SECTION

I. General Information and Genetic Background

• Vector Type: Prokaryote Expression Vector (Mycoplasma genus-specific stable expression plasmid system).

• Species Compatibility: Tailored for Mycoplasma pneumoniae, Mycoplasma genitalium, Mycoplasma capricolum, Mycoplasma mycoides, and related species.

• Genetic Code Specificity (Codon Optimization Core):

  • Critical Translational Barrier: The genus Mycoplasma utilizes a non-standard genetic code where the UGA codon is reassigned from a stop codon to code for Tryptophan (Trp).

  • Design Obligation: Standard E. coli vectors will cause premature translation termination at UGA sites. This system utilizes a custom framework tailored for mycoplasmal translation. When cloning target genes, codon selection must match this reassignment for robust product yielding inside the mycoplasma host.

• Replicon & Maintenance Elements:

  • Equipped with a mycoplasma-specific chromosomal origin of replication (oriC) derived from endogenous plasmids (e.g., pGyl analogues), guaranteeing stable partitioning during binary fission.

  • Contains a standard E. coli replicon (such as pUC ori) for high-copy cloning and easy plasmid preparation inside standard enterobacterial strains.

• Selection Marker: Commonly driven by a strong constitutively active mycoplasmal promoter upstream of either a tetracycline resistance gene (tetM) or an erythromycin resistance gene (ermB) for selective screening post-transformation.

II. Molecular Architecture and Cloning Settings

• Promoter System: Governed by high-efficiency house-keeping mycoplasmal promoters, such as the elongation factor tu promoter (P_tuf) or the ribosomal protein subunit D promoter (P_rpsD), ensuring strong, continuous, constitutive transcription without requiring chemical inducers.

• Multiple Cloning Site (MCS): Furnished with unique restriction sites (e.g., BamHI, EcoRI, XhoI, HindIII) to simplify directional insertion of target genes.

• Epitope Tagging Options: Available with terminal 6×His-tag or Flag-tag options at either the N- or C-terminus, streamlining Western Blot profiling and affinity chromatography capture processing.

• Biosafety Level: BSL-1 (for the naked plasmid) / BSL-2 (post-transformation). The vector itself is non-hazardous. However, once introduced into pathogenic strains like M. pneumoniae, all downstream culture lines must be contained within Class II Biosafety Cabinets.

III. Transformation and Selection Protocols

1. Plasmid Amplification in E. coli:

   • Transform the expression construct into standard E. coli competent cells (e.g., DH5α, Top10) and plate on LB agar supplemented with the appropriate selection agent.

   • Isolate the plasmid using an endotoxin-free or high-purity miniprep kit and confirm the integrity of the MCS insertion profile via Sanger sequencing.

2. Mycoplasma Electroporation:

   • Harvest mycoplasma liquid cultures during the late exponential growth phase. Wash cells multiple times with an ice-cold, high-osmolarity wash buffer (e.g., 8-272 mM sucrose matrix) to yield dense electrocompetent mycoplasma cells.

   • Aliquot 50–100 μL of competent cells into a pre-chilled electroporation cuvette, mix with 1–5 μg of pure plasmid DNA, and incubate briefly on ice.

   • Apply an electrical pulse customized for small, wall-less prokaryotes (typical parameters: voltage 1.25–2.5 kV, capacitance 25 μF, resistance 100–400 Ω).

   • Immediately rescue the shocked cells by adding pre-warmed complete mycoplasma broth (e.g., SP4 or Hayflick medium) and incubate non-selectively at 37°C for 2–4 hours to facilitate membrane repair and marker expression.

3. Antibiotic Selection Plating:

   • Spread the recovered pool onto solid mycoplasma agar plates containing appropriate selective screening agents (e.g., 2–10 μg/mL tetracycline or erythromycin).

   • Incubate at 37°C (or under a 5% $CO_2$ microaerophilic atmosphere) for 5–14 days until characteristic "fried-egg" morphology colonies emerge.

IV. Strategic Research Applications

1. Gene Function Validation & Genetic Complementation: Used to re-introduce wild-type genes back into knockout mutants or attenuated mycoplasma strains to restore phenotype markers, confirming the exact function of suspected virulence factors or adhesins.

2. Surface Antigen Presentation & Vaccine Development: Enables native conformation-dependent expression of surface-exposed membrane proteins, which is critical for evaluating host-pathogen dynamics or screening antigen targets for subunit vaccine development.

3. Host-Pathogen Interaction Mapping: Facilitates real-time tracking, attachment tracing, and intracellular colonization profiling against host epithelial cells via translational fusion with fluorescent reporters like GFP or mCherry.

BioVector NTCC质粒载体菌株细胞蛋白抗体基因保藏中心

电话:400-800-2947

工作QQ/微信同号:1843439339

网址

http://www.biovector.net